shutterstock_619031537_castleski-1

Castleski / Shutterstock.com

23 June 2021Big PharmaAlex Baldwin

Pharma company fails to block €140m licence payment

Taiwanese pharmaceutical company PharmaEssentia Corporation (PEC) has failed to convince a district court judge to throw out a €140 million award to AOP Orphan Pharmaceuticals (AOP).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Amgen successfully blocks sale of Sandoz’s Zarxio biosimilar

7 May 2015 The US Court of Appeals for the Federal Circuit has blocked US sales of Sandoz’s Zarxio, the biosimilar version of Amgen’s Neupogen, an injection used to prevent infection in patients undergoing chemotherapy.

Biogen blocking bid rejected; signs $2.4bn deal

28 February 2020 The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.

More on this story

Amgen successfully blocks sale of Sandoz’s Zarxio biosimilar

7 May 2015 The US Court of Appeals for the Federal Circuit has blocked US sales of Sandoz’s Zarxio, the biosimilar version of Amgen’s Neupogen, an injection used to prevent infection in patients undergoing chemotherapy.

Biogen blocking bid rejected; signs $2.4bn deal

28 February 2020 The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.

More on this story

Amgen successfully blocks sale of Sandoz’s Zarxio biosimilar

7 May 2015 The US Court of Appeals for the Federal Circuit has blocked US sales of Sandoz’s Zarxio, the biosimilar version of Amgen’s Neupogen, an injection used to prevent infection in patients undergoing chemotherapy.

Biogen blocking bid rejected; signs $2.4bn deal

28 February 2020 The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a bioequivalent version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent